Drugs / CS32582
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06224595 | Mar → Nov 2024 | — | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07129382 | Sep 2025 → Sep 2027 expected | psoriasis | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS32582 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06224595 ↗ |
| Route | Oral | “Participants receive CS32582 orally single or multiple doses” NCT06224595 ↗ |